Effects of ospemifene on overactive bladder in postmenopausal women with vulvovaginal atrophy

Overactive bladder (OAB) is a complex and multifactorial syndrome associated with urinary frequency, urgency and incontinence. The menopause-associated hormonal changes play a role in the development of this condition. Vaginal estrogens are effective in improving OAB in postmenopausal women (PMW) wi...

Full description

Saved in:
Bibliographic Details
Published in:Climacteric : the journal of the International Menopause Society 2023-06, Vol.26 (3), p.284-288
Main Authors: Russo, E., Misasi, G., Montt-Guevara, M. M., Giannini, A., Simoncini, T.
Format: Article
Language:English
Subjects:
aging
Atrophy - drug therapy
Bladder
Female
Humans
menopause
ospemifene
Overactive bladder
Postmenopause
Quality of Life
Questionnaires
selective estrogen receptor modulator
Treatment Outcome
Urinary Bladder, Overactive - drug therapy
Urinary incontinence
Urinary Incontinence - drug therapy
vulvovaginal atrophy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Overactive bladder (OAB) is a complex and multifactorial syndrome associated with urinary frequency, urgency and incontinence. The menopause-associated hormonal changes play a role in the development of this condition. Vaginal estrogens are effective in improving OAB in postmenopausal women (PMW) with vulvovaginal atrophy (VVA). Ospemifene is a selective estrogen receptor modulator licensed for the treatment of VVA. This study aimed to evaluate the effects of ospemifene on OAB symptoms in PMW with VVA. Forty PMW suffering from OAB and VVA received oral ospemifene (60 mg/day) for 12 weeks. All patients were assessed with a urodynamic study, a 3-day bladder diary and validated questionnaires (International Consultation on Incontinence Questionnaire - Urinary Incontinence Short Form [ICIQ-UI SF] and International Consultation on Incontinence Questionnaire - Overactive Bladder [ICIQ-OAB]) at enrollment and at the end of the study. Cytometric capacity, bladder compliance and verbal sensory threshold responses during bladder filling were improved after treatment. The voiding diary showed a significant reduction of daily voids, urge urinary incontinence episodes and nocturnal events. The median overall scores of the ICIQ-UI and ICIQ-OAB were also significantly improved. Our study suggest that treatment with ospemifene in PMW suffering from OAB is associated with a reduction of OAB symptoms due to a decreased bladder sensitivity and with an improvement in quality of life.
ISSN:1369-7137
1473-0804
DOI:10.1080/13697137.2023.2184251